Report Details

Where are antithrombotic and anticoagulant treatments heading? Visiongain's report shows you potential revenues to 2022, with data, forecasts and discussions.

This study assesses drugs to treat abnormal blood clotting in human beings. Discover sales predictions at world market, therapeutic class, product and national levels to 2022. 

How will products - Plavix, Lovenox, Pletal, Fragmin, Asasantin, Arixtra, Aspirin Cardio, Effient, Pradaxa, Brilinta and others - perform? Our report gives you business research and analysis with many sales predictions. See the future of the industry and market. 

Also, receive forecasting of submarkets, finding potential sales trends from 2012: 
• Platelet aggregation inhibitors
• Heparins
• Fibrinolytics
• Vitamin K antagonists
• Direct thrombin inhibitors
• Direct factor Xa inhibitors.

Our report discusses activities of Eli Lilly, Boehringer Ingelheim, AstraZeneca, J&J, Bayer, Sanofi, Merck, Eisai, Daiichi Sankyo and other pharmaceutical companies. 

What does the future hold? With its R&D pipelines, the pharma industry has potential for improved treatments and increased revenues from blood-thinning agents. Many commercial opportunities remain. 

Worldwide, numbers of heart attacks and strokes will rise this decade. Blood thinners will play important roles in medicine, helping to prevent and treat cardiovascular disorders.

Visiongain's study provides data, analysis and opinion aiming to benefit your research, calculations, meetings and presentations. You will find answers in our work.

Revenue forecasts, market shares, developmental trends, discussions and interviews

In the report you find revenue forecasting, growth rates, market shares, qualitative analyses (including SWOT and STEP), opinions and R&D news. You receive 82 tables and charts and four research interviews.

Advantages of Antithrombotic/Anticoagulant Drugs: World Market 2012-2022 for your work

In particular, this study gives you the following knowledge and benefits:
• Find revenue predictions to 2022 for the overall world market and submarkets
• Discover revenue forecasts to 2022 for 14 drugs, assessing commercial potential
• See revenue forecasts to 2022 for leading national markets - US, Japan, Germany, France, UK,Spain, Italy, China and India
• Assess leading companies, discovering activities and outlooks
• Review R&D, seeing pipeline trends
• Investigate competition and opportunities influencing sales results
• Find out what will stimulate and restrain the industry and market
• View opinions from our survey of authorities on the sector.

There, you receive a distinctive mix of quantitative and qualitative work with independent predictions. We analyse developments and prospects, helping you to stay ahead.

Gain business research, data and analysis for treatment of blood clotting disorders 

Our study is for everybody needing industry and market analyses for blood-thinning drugs. Find data, trends and answers. Avoid missing out - please order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6 

Table Of Contents

Table of Contents

1. Executive Summary
1.1 Antithrombotic/Anticoagulant Drug: World Market Overview
1.2 Aims, Scope and Format of the Report
1.3 Research and Analysis Methods

2. Blood Clotting: Mechanism, Disorders and Treatments 
2.1 Thrombosis
2.1.1 Venous Thrombosis
2.1.2 Arterial Thrombosis
2.2 Complications of Thrombosis
2.2.1 Pulmonary Embolism
2.2.2 Stroke
2.2.3 Myocardial Infarction
2.2.4 Acute Coronary Syndrome
2.3 Antithrombotic Treatments
2.3.1 Platelet Aggregation Inhibitors
2.3.1.1 Glycoprotein Inhibitors
2.3.1.2 Aspirin
2.3.1.3 Thienopyridines
2.3.2 Heparins
2.3.3 Fibrinolytics
2.3.3.1 Streptokinase and Urokinase
2.3.3.2 Tissue Plasminogen Activator (tPA)
2.3.3.3 Other Thrombolytic Agents
2.3.4 Vitamin K Antagonists
2.3.5 Direct Thrombin Inhibitors
2.3.6 Direct Factor Xa Inhibitors

3. Antithrombotic Drugs: World Market 2012-2022
3.1 The Antithrombotic/Anticoagulant Drug Market in 2010
3.2 The Antithrombotic/Anticoagulant Drug Market Forecast 2012-2022
3.3 The Leading Antithrombotic/Anticoagulant Therapeutic Classes
3.3.1 The Leading Therapeutic Classes in 2010
3.3.2 Leading Therapeutic Class Forecast 2012-2022
3.4 Platelet Aggregation Inhibitors
3.4.1 Platelet Aggregation Inhibitors Dominated the Market in 2010
3.4.2 Platelet Aggregation Inhibitors: Market Forecast 2012-2022
3.5 Heparins
3.5.1 The Heparins Market in 2010
3.5.2 Heparins: Market Forecast 2012-2022
3.6 Fibrinolytics
3.6.1 The Fibrinolytics Market in 2010
3.6.2 Fibrinolytics: Market Forecast 2012-2022
3.7 Vitamin K Antagonists
3.7.1 Vitamin K Antagonists Market in 2010
3.7.2 Vitamin K Antagonists Market Forecast 2012-2022
3.8 Direct Thrombin Inhibitors
3.8.1 Direct Thrombin Inhibitors Market in 2010
3.8.2 Direct Thrombin Inhibitors: Market Forecast 2012-2022
3.9 Direct Factor Xa Inhibitors
3.9.1 Direct Factor Xa Inhibitors Market in 2010
3.9.2 Direct Factor Xa Inhibitors: Market Forecast 2012-2022
3.10 Chapter Summary

4. Leading National Markets for Antithrombotic/Anticoagulant Drugs, 2012-2022
4.1 Leading National Markets in 2010
4.2 Leading National Markets: Forecasts to 2022
4.3 The US Antithrombotic/Anticoagulant Drug Market, 2012-2022
4.4 The Japanese Antithrombotic/Anticoagulant Drug Market, 2012-2022
4.5 Leading European Antithrombotic/Anticoagulant Drug Markets, 2012-2022
4.6 The Chinese Antithrombotic/Anticoagulant Drug Market, 2012-2022
4.7 The Indian Antithrombotic/Anticoagulant Drug Market, 2012-2022

5. Leading Antithrombotic/Anticoagulant Drugs, 2012-2022
5.1 The Leading Drugs of 2010
5.2 Plavix - Commercial Prospects
5.2.1 Plavix: The Leading Anticoagulant of 2010
5.2.2 Plavix Sales Forecast, 2012-2022
5.2.3 Generic Competition
5.2.4 Branded Competition
5.3 Lovenox
5.3.1 Lovenox Sales Forecast, 2012-2022
5.3.2 Competition for Lovenox
5.4 Pletal
5.4.1 Pletal Sales, 2010
5.4.2 Pletal Sales Forecast, 2012-2022
5.5 Fragmin
5.5.1 Fragmin Sales, 2010
5.5.2 Fragmin Sales Forecast, 2012-2022
5.6 Asasantin
5.6.1 Asasantin Sales, 2010
5.6.2 Asasantin Sales Forecast, 2012-2022
5.7 Arixtra
5.7.1 Arixtra Sales, 2010
5.7.2 Arixtra Sales Forecast, 2012-2022
5.8 Aspirin Cardio
5.8.1 Aspirin Cardio Sales, 2010
5.8.2 Aspirin Cardio Sales Forecast, 2012-2022
5.9 Opalmon
5.9.1 Opalmon Sales, 2010
5.9.2 Opalmon Sales Forecast, 2012-2022
5.10 Angiomax
5.10.1 Angiomax Sales, 2010
5.10.2 Angiomax Sales Forecast, 2012-2022
5.11 Activase
5.11.1 Activase Sales, 2010
5.11.2 Activase Sales Forecast, 2012-2022
5.12 Newly Launched Drugs, 2009-2011 
5.12.1 Eli Lilly's Effient
5.12.1.1 Effient Sales Forecast, 2012-2022 
5.12.1.2 Competition for Effient
5.12.2 Boehringer Ingelheim's Pradaxa 
5.12.2.1 Pradaxa Sales Forecast, 2012-2022 
5.12.2.2 Compe

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • August 2014
  • by Global Data

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023 Summary Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented ...

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  • $ 10 995
  • Industry report
  • September 2014
  • by Global Data

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary During the forecast period from 2012-2022, the growth of the UC market will be driven largely ...

Cancer Vaccines: Technologies and Global Markets

Cancer Vaccines: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • Dec 2014
  • by BCC Research

REPORT HIGHLIGHTS The global market for cancer vaccines was about $4.5 billion in 2013. This market reached about $4.0 billion in 2014 and is expected to reach $4.3 billion in 2019, registering a compound ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.